STOCK TITAN

Actinium Pharmaceuticals Inc - ATNM STOCK NEWS

Welcome to our dedicated news page for Actinium Pharmaceuticals (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Actinium Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Actinium Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.75%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.16%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.64%
Tags
management clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
clinical trial
Actinium Pharmaceuticals Inc

NYSE:ATNM

ATNM Rankings

ATNM Stock Data

217.39M
26.64M
2.32%
26.31%
6.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ATNM

actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o